A post-FDA approval study of Abbott’s CardioMEMS heart failure sensor found the device reduced HF-related hospitalizations by 58 percent in a trial group of 1,200 patients, researchers reported at this year’s American College of Cardiology symposium in New Orleans.

A catheter ablation protocol for atrial fibrillation (AFib) including only “the bare essentials” of the procedure delivered similar outcomes as a more involved strategy featuring pulmonary vein mapping, according to research presented at EHRA 2019.

Intravascular ultrasound (IVUS)-guided PCI was associated with lower long-term risk of cardiac death than an angiography-guided approach in patients with complex lesions, according to a single-center study published in JACC: Cardiovascular Interventions.

A remote monitoring protocol for heart failure patients with implantable electronic devices helped more of them stay out of the hospital over a one-year period than standard in-person visits, researchers reported at EHRA 2019.

Richard Kovacs, MD, officially began his one-year stint as the president of the American College of Cardiology on March 18. The occasion was marked during a convocation ceremony on the final day of the ACC’s scientific sessions in New Orleans.

NEW ORLEANS — A new analysis considering not only a patient's first cardiovascular event—but the second, third and beyond—paints the REDUCE-IT trial in an even more positive light. 

NEW ORLEANS — An antithrombotic regimen of apixaban plus a P2Y12 inhibitor such as clopidogrel lowered bleeding events and hospitalizations compared to warfarin plus clopidogrel in a cohort of patients with atrial fibrillation (AFib) and a recent acute coronary syndrome (ACS), according to results of the AUGUSTUS trial.